About Unconventional myosin-Ib
Unconventional myosin-Ib (MYO1B) is a protein
from Homo sapiens identified by UniProt accession
O43795, 1136 residues long.
MolForge cross-references it against 0 known binders and
65 disease associations.
Target properties
| Protein name | Unconventional myosin-Ib |
|---|
| UniProt accession | O43795 |
|---|
| Gene | MYO1B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1136 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (65)
Diseases linked to this target (Open Targets).
- serum gamma-glutamyl transferase measurement · score 0.45
- alkaline phosphatase measurement · score 0.42
- hair color · score 0.36
- colorectal cancer · score 0.33
- adolescent idiopathic scoliosis · score 0.31
- hair colour measurement · score 0.29
- platelet count · score 0.28
- rheumatoid arthritis · score 0.22
- head and neck squamous cell carcinoma · score 0.09
- neoplasm · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43795-F1 | alphafold | PREDICTED | 85.89 | — |
Amino-acid sequence (1136 residues)
MAKMEVKTSL LDNMIGVGDM VLLEPLNEET FINNLKKRFD HSEIYTYIGS VVISVNPYRS LPIYSPEKVE EYRNRNFYEL SPHIFALSDE AYRSLRDQDK DQCILITGES GAGKTEASKL VMSYVAAVCG KGAEVNQVKE QLLQSNPVLE AFGNAKTVRN DNSSRFGKYM DIEFDFKGDP LGGVISNYLL EKSRVVKQPR GERNFHVFYQ LLSGASEELL NKLKLERDFS RYNYLSLDSA KVNGVDDAAN FRTVRNAMQI VGFMDHEAES VLAVVAAVLK LGNIEFKPES RVNGLDESKI KDKNELKEIC ELTGIDQSVL ERAFSFRTVE AKQEKVSTTL NVAQAYYARD ALAKNLYSRL FSWLVNRINE SIKAQTKVRK KVMGVLDIYG FEIFEDNSFE QFIINYCNEK LQQIFIELTL KEEQEEYIRE DIEWTHIDYF NNAIICDLIE NNTNGILAML DEECLRPGTV TDETFLEKLN QVCATHQHFE SRMSKCSRFL NDTSLPHSCF RIQHYAGKVL YQVEGFVDKN NDLLYRDLSQ AMWKASHALI KSLFPEGNPA KINLKRPPTA GSQFKASVAT LMKNLQTKNP NYIRCIKPND KKAAHIFNEA LVCHQIRYLG LLENVRVRRA GYAFRQAYEP CLERYKMLCK QTWPHWKGPA RSGVEVLFNE LEIPVEEYSF GRSKIFIRNP RTLFKLEDLR KQRLEDLATL IQKIYRGWKC RTHFLLMKKS QIVIAAWYRR YAQQKRYQQT KSSALVIQSY IRGWKARKIL RELKHQKRCK EAVTTIAAYW HGTQARRELR RLKEEARNKH AIAVIWAYWL GSKARRELKR LKEEARRKHA VAVIWAYWLG LKVRREYRKF FRANAGKKIY EFTLQRIVQK YFLEMKNKMP SLSPIDKNWP SRPYLFLDST HKELKRIFHL WRCKKYRDQF TDQQKLIYEE KLEASELFKD KKALYPSSVG QPFQGAYLEI NKNPKYKKLK DAIEEKIIIA EVVNKINRAN GKSTSRIFLL TNNNLLLADQ KSGQIKSEVP LVDVTKVSMS SQNDGFFAVH LKEGSEAASK GDFLFSSDHL IEMATKLYRT TLSQTKQKLN IEISDEFLVQ FRQDKVCVKF IQGNQKNGSV PTCKRKNNRL LEVAVP
Explore Unconventional myosin-Ib with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets